ARWR - Arrowhead Pharmaceuticals GAAP EPS of -$0.68 misses by $0.21 revenue of $32.41M misses by $20.2M
- Arrowhead Pharmaceuticals press release ( NASDAQ: ARWR ): FQ3 GAAP EPS of -$0.68 misses by $0.21 .
- Revenue of $32.41M (-29.4% Y/Y) misses by $20.2M .
- During the quarter, the company formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China.
For further details see:
Arrowhead Pharmaceuticals GAAP EPS of -$0.68 misses by $0.21, revenue of $32.41M misses by $20.2M